Epsilon Healthcare has posted a record $2.891 million in receipts for the December 2025 quarter, nearly doubling year-on-year revenue and marking a significant turnaround with its recent ASX reinstatement.
- 96% year-on-year growth in December quarter receipts
- Reinstated to ASX quotation on 19 December 2025
- Full year receipts up 71% to $9.175 million
- Strong growth across contract manufacturing, clinics, and pharmacy
- New retail pharmacy site planned for Q1 2026
Record Quarter Caps Successful Turnaround
Epsilon Healthcare Limited (ASX – EPN) has delivered a standout performance in the December 2025 quarter, reporting a record $2.891 million in receipts; a 96% increase compared to the same period last year. This milestone not only underscores the company’s robust recovery but also coincides with its reinstatement to ASX quotation on 19 December 2025, a pivotal moment after a challenging period marked by administration.
For the full year ending 31 December 2025, Epsilon’s consolidated receipts reached $9.175 million, up 71% from $5.373 million in 2024. The company’s revenue run-rate now exceeds $1 million per month, reflecting sustained demand across its diversified healthcare operations.
Diversified Growth Across Subsidiaries
The growth was broad-based, with Epsilon Pharma’s contract development and manufacturing arm in Southport securing new domestic and international clients, driving increased manufacturing volumes. This division’s strong compliance with Good Manufacturing Practice (GMP) standards has positioned it as a trusted partner in natural medicines and active pharmaceutical ingredients, fueling its expanding pipeline.
Epsilon Clinics maintained steady patient engagement and recurring earnings, leveraging an integrated telehealth model that enhances patient care and retention. Meanwhile, the newly launched Epsilon Pharmacy, operational since February 2025, has rapidly scaled and is set to open a new high street retail pharmacy in Q1 2026, further strengthening the company’s integrated healthcare ecosystem.
Financial Discipline and Strategic Outlook
Despite increased operating costs and labour expenses, Epsilon has managed a disciplined approach to capital structure and liquidity. The company reported $242,000 in cash at quarter-end and maintains $2 million in unused financing facilities, providing a runway of approximately 3.6 quarters of funding. Receipt of a $299,000 R&D tax incentive during the quarter supports ongoing innovation efforts.
Managing Director Peter Giannopoulos highlighted the company’s clear pathway to sustainable profitability, driven by operating leverage and a growing pipeline of opportunities. The planned pharmacy expansion and international client acquisitions are expected to further diversify revenue streams and enhance shareholder value.
Looking Ahead
As Epsilon Healthcare enters 2026, it stands at a critical juncture, balancing rapid growth with the need to improve margins and capital efficiency. The company’s integrated model combining manufacturing, clinics, and pharmacy services offers a unique platform for scalable healthcare delivery. Investors will be watching closely to see how this momentum translates into profitability and long-term value creation.
Bottom Line?
Epsilon’s impressive revenue surge and ASX reinstatement set the stage for a pivotal 2026 focused on scaling and profitability.
Questions in the middle?
- Can Epsilon sustain its rapid revenue growth while improving margins?
- How will the new retail pharmacy impact overall profitability and brand presence?
- What progress will be made in expanding international contract manufacturing clients?